GlassScriptPhysician profile
Manjula Tella
NPI 1811050644
$4,537.44
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $1,753 · 2021: $929 · 2022: $587 · 2023: $577 · 2024: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $569 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $568.81 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $2,240.75 | 2019-2022 | |
| Biogen, INC. | $448.70 | 2019-2023 | Vumerity |
| Abbvie INC. | $425.16 | 2021-2024 | Qulipta, Ubrelvy, Botox |
| Teva Pharmaceuticals USA, INC. | $280.22 | 2019-2023 | Austedo Xr, Ajovy, Austedo |
| Lilly USA, LLC | $161.77 | 2022-2023 | Emgality, Amyvid |
| Biohaven Pharmaceuticals, INC. | $161.36 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $159.13 | 2022 | |
| Novartis Pharmaceuticals Corporation | $154.05 | 2020-2023 | |
| Otsuka America Pharmaceutical, INC. | $73.16 | 2023-2024 | Nuedexta |
| Mallinckrodt Hospital Products INC. | $64.65 | 2021-2023 | Acthar |
| Neurocrine Biosciences, INC. | $46.60 | 2020 | |
| Mdd US Operations, LLC | $43.94 | 2022 | |
| Sk Life Science, INC. | $43.79 | 2022 | |
| Amneal Pharmaceuticals LLC | $43.02 | 2023 | Rytary |
| Lundbeck LLC | $31.54 | 2020-2023 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $31.24 | 2022-2024 | Inbrija |
| Neurelis, INC. | $31.05 | 2024 | Valtoco |
| Ucb, INC. | $24.21 | 2022 | |
| Avion Pharmaceuticals | $12.80 | 2022 | |
| Tanabe Pharma America, INC. | $12.27 | 2021 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Upsher-Smith Laboratories LLC | $11.81 | 2022 | |
| Emd Serono, INC. | $11.71 | 2019 | |
| Ge Healthcare | $9.00 | 2021 | |
| Grt US Holding, INC. | $3.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manjula Tella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.